Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Lymphoma Diagnosis and Classification Using Next Generation Sequencing of 30 CD Markers and Machine Learning As an Alternative to Immunohistochemistry

Maher Albitar, Hong Zhang, Andrew Ip, Wanlong Ma, Jeffrey Justin Estella, Lori A. Leslie, Tatyana Feldman, Ahmad Charifa, Arash Mohtashamian, Andrew L Pecora, Andre Goy

Blood (2023) 142 (Supplement 1): 3665.

https://doi.org/10.1182/blood-2023-187534

Published: 2023

Journal Articles

Impact of Response to Systemic Bridging Therapy on Clinical Outcomes and Cytokine Profiles in Patients Receiving CD19- CAR T-Cell Therapy for B-Cell Lymphoma

Beatriz Wills, Roni Shouval, Jessica R. Flynn, Sean M. Devlin, Allison Parascondola, Amethyst Saldia, Brandon S. Imber, Ana Alarcon Tomas, Ivan Landego, Richard J. Lin, Michael Scordo, Parastoo Bahrami Dahi, Gunjan L. Shah, Andrew Ip, Lori A Leslie, Hyung Chan Suh, Gilles Salles, Miguel-Angel Perales, Maria Lia Palomba

Blood (2023) 142 (Supplement 1): 3014.

https://doi.org/10.1182/blood-2023-181116

Published: 2023

Journal Articles

Comparison of Bendamustine Versus Fludarabine/ Cyclophosphamide Lymphodepletion in Adult Patients Receiving CD19 CAR-T Cell Therapy

Blood (2023) 142 (Supplement 1): 3510.

https://doi.org/10.1182/blood-2023-189349

Published: 2023

Journal Articles

Outcomes Analysis of Lenalidomide-Induced Rashes in Myeloma Patients

James Behrmann, Robert J Vanaria, Shannon Meledathu, Aishwarya Sridhar, Michael Povelaitis, Harsh Parmar, Andrew Ip

Blood (2023) 142 (Supplement 1): 6689.

https://doi.org/10.1182/blood-2023-184906

Published: 2023

Journal Articles

Outcomes of Patients with Primary Mediastinal B-Cell Lymphoma Refractory or Relapsed after Frontline R-EPOCH Chemotherapy

Jonathan Bakos, Silvia Escribano Serrat, Yazeed Sawalha, Alison Moskowitz, Anna Crawford, Taylor R. Brooks, Brian T. Hill, Ayo S Falade, Reid W. Merryman, Manali Kamdar, Andrew Ip, Gunjan L. Shah, Arash Velayati, McKenzie Sorrell, James A Davis, Irl Brian Greenwell, Ann LaCasce, Brian Hess

Blood (2023) 142 (Supplement 1): 3110.

https://doi.org/10.1182/blood-2023-178740

Published: 2023

Journal Articles

Retrospective Review of Patients Treated with Intrathecal Rituximab for Primary and Secondary CNS Lymphoma and Leukemia

Tatyana Feldman, Alexandra Della Pia, Geeny Lee, Thomas S. Gunning, Michael Pelliccia, Tony Varughese, Harsh Parmar, Andrew Ip, Lori A. Leslie, Andre Goy, Samuel Singer

Blood (2023) 142 (Supplement 1): 1773.

https://doi.org/10.1182/blood-2023-187164

Published: 2023

Journal Articles

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of CLN-978 (CD19XCD3XHSA) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Geoffrey P. Shouse, Kristie A. Blum, Julie E. Haydu, Jeremy S. Abramson, Mayur Narkhede, Andrew Ip, Jennifer S. Michaelson, Patrick A. Baeuerle, Kristan Meetze, Irina Shapiro, Todd Shearer, Judith Inumerable, Jeff Jones, Farrukh T. Awan

Blood (2023) 142 (Supplement 1): 3142.

https://doi.org/10.1182/blood-2023-181239

Published: 2023

Journal Articles

Digital Health Literacy in Patients with Non-Hodgkin Lymphoma: Informing Intervention Approaches to Address Financial Toxicity

Thomas S. Gunning, Amanda Khoudary, Isabella Westervelt, Osairys Billini, Andrew Ip, Chadane Thompson, Lia Sorgen, Arnold Potosky, Marc Schwartz, Claire C. Conley, Heather M. Derry-Vick

Blood (2023) 142 (Supplement 1): 7348.

https://doi.org/10.1182/blood-2023-175021

Published: 2023

Journal Articles

Polygenic HLA-Class I and HLA-Class II Models Define Various Types of Lymphoma

Maher Albitar, Hong Zhang, Andrew Ip, Gustavo A. Rivero, Wanlong Ma, Jeffrey Justin Estella, Lori A. Leslie, Tatyana Feldman, Ahmad Charifa, Arash Mohtashamian, Andrew L Pecora, Andre Goy

Blood (2023) 142 (Supplement 1): 6110.

https://doi.org/10.1182/blood-2023-187686

Published: 2023

Journal Articles

Deregulation of HLA-Class I and Class II Genes in Chip, MDS, and Acute Leukemia and Similarity between Chip and MDS in HLA Profile

Maher Albitar, Hong Zhang, Andrew Ip, Gustavo A. Rivero, Wanlong Ma, James McCloskey, Katherine Linder, Jeffrey Justin Estella, Jamie Koprivnikar, Ahmad Charifa, Arash Mohtashamian, Andrew L Pecora, Andre Goy

Blood (2023) 142 (Supplement 1): 5688.

https://doi.org/10.1182/blood-2023-187606

Published: 2023

Journal Articles

Using Next Generation Sequencing of Flow Cytometry CD Markers and Machine Learning As a Replacement to Flow Cytometry Analysis for the Diagnosis of Hematologic Neoplasms

Maher Albitar, Hong Zhang, Andrew Ip, Wanlong Ma, James McCloskey, Katherine Linder, Jeffrey Justin Estella, Jamie Koprivnikar, Noa Biran, David S. Siegel, Ahmad Charifa, Arash Mohtashamian, Andrew L Pecora, Andre Goy

Blood (2023) 142 (Supplement 1): 3654.

https://doi.org/10.1182/blood-2023-187041

Published: 2023

Journal Articles

DNA and RNA Profiles in Machine Learning Algorithm to Predict Which Patients with AML/MDS Will Respond to Venetoclax-Based Therapy

Maher Albitar, Andrew Ip, Andre H. Goy, Katherine Linder, Jeffrey Justin Estella, Ahmad Charifa, Wanlong Ma, Andrew L. Pecora, Jamie Koprivnikar, James McCloskey

Blood (2022) 140 (Supplement 1): 6270–6271.

https://doi.org/10.1182/blood-2022-167406

Published: 2022

Journal Articles

Dose-Intense Frontline Chemotherapy Changes Molecular Classifier Prognostication in Diffuse Large B-Cell Lymphoma(DLBCL)

Tatyana Feldman, Maher Albitar, Hong Cheng, Kar Chow, Alessandra Petrillo, Ahmetmursel Ulusan, Andrew Ip, Alexandra Della Pia, Gabriella Magarelli, Brittany Lukasik, Lori Leslie, Pritish K. Bhattacharyya, Andrew L. Pecora, Andre H. Goy

Blood (2022) 140 (Supplement 1): 11893–11895.

https://doi.org/10.1182/blood-2022-169586

Published: 2022

Journal Articles

Liquid Immunophenotyping and the Diagnosis of Lymphoid Neoplasms Using Cell-Free RNA

Maher Albitar, Hong Zhang, Andrew Ip, Jeffrey Justin Estella, Ahmad Charifa, Wanlong Ma, Ipsa Sharma, Andrew L. Pecora, Lori Leslie, Tatyana Feldman, Andre H. Goy

Blood (2022) 140 (Supplement 1): 7828–7829.

https://doi.org/10.1182/blood-2022-162590

Published: 2022

Journal Articles

Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium

Blood (2022) 140 (Supplement 1): 1588–1591.

https://doi.org/10.1182/blood-2022-164674

Published: 2022

Journal Articles

Real-World Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Standard of Care: A Cota Database Analysis

Andrew Ip, Alex Mutebi, Tongsheng Wang, Monika P. Jun, Anupama Kalsekar, Fernando Rivas Navarro, Anthony Wang, Rajesh Kamalakar, Mariana Sacchi, Brian Elliott

Blood (2022) 140 (Supplement 1): 6693–6694.

https://doi.org/10.1182/blood-2022-159569

Published: 2022

Journal Articles

Using Targeted Transcriptome and Machine Learning of Pre- and Post-Transplant Bone Marrow Samples to Predict Acute Gvhd (aGVHD) and Overall Survival after Allogeneic HSC Transplantation

Maher Albitar, Hong Zhang, Andrew L. Pecora, Andrew Ip, Andre H. Goy, Spiraggelos Antzoulatos, Wanlong Ma, Sukhdeep Kaur, Hyung C. Suh, Michele L. Donato, Scott D. Rowley

Blood (2022) 140 (Supplement 1): 4757–4758.

https://doi.org/10.1182/blood-2022-162816

Published: 2022

Journal Articles

Reliability of Cell-Free DNA (cfDNA) Next Generation Sequencing in Predicting Chromosomal Structural Abnormalities and Cytogenetic-Risk Stratification of Patients with Myeloid Neoplasms

Maher Albitar, Andrew Ip, Andre H. Goy, Jeffrey Justin Estella, Ivan De Dios, Wanlong Ma, Andrew L. Pecora, Jamie Koprivnikar, James K McCloskey

Blood (2021) 138 (Supplement 1): 3463.

https://doi.org/10.1182/blood-2021-148164

Published: 2021

Journal Articles

A Multi-Center Retrospective Study of Polatuzumab for Patients with Large B-Cell Lymphoma Relapsed after Standard of Care CAR T-Cell Therapy

Sushanth Gouni, Allison C. Rosenthal, Jennifer L. Crombie, Andrew Ip, Manali Kamdar, Brian T. Hess, Lei Feng, Grace Watson, Amy Ayers, Sattva S. Neelapu, Arushi Khurana, Madiha Iqbal, Yi Lin, Reid W Merryman, Paolo Strati

Blood (2021) 138 (Supplement 1): 2495.

https://doi.org/10.1182/blood-2021-147591

Published: 2021

Journal Articles

Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy

Blood (2021) 138 (Supplement 1): 165.

https://doi.org/10.1182/blood-2021-145764

Published: 2021

NARROW

Lymphoma Diagnosis and Classification Using Next Generation Sequencing of 30 CD Markers and Machine Learning As an Alternative to Immunohistochemistry

Impact of Response to Systemic Bridging Therapy on Clinical Outcomes and Cytokine Profiles in Patients Receiving CD19- CAR T-Cell Therapy for B-Cell Lymphoma

Comparison of Bendamustine Versus Fludarabine/ Cyclophosphamide Lymphodepletion in Adult Patients Receiving CD19 CAR-T Cell Therapy

Outcomes Analysis of Lenalidomide-Induced Rashes in Myeloma Patients

Outcomes of Patients with Primary Mediastinal B-Cell Lymphoma Refractory or Relapsed after Frontline R-EPOCH Chemotherapy

Retrospective Review of Patients Treated with Intrathecal Rituximab for Primary and Secondary CNS Lymphoma and Leukemia

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of CLN-978 (CD19XCD3XHSA) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Digital Health Literacy in Patients with Non-Hodgkin Lymphoma: Informing Intervention Approaches to Address Financial Toxicity

Polygenic HLA-Class I and HLA-Class II Models Define Various Types of Lymphoma

Deregulation of HLA-Class I and Class II Genes in Chip, MDS, and Acute Leukemia and Similarity between Chip and MDS in HLA Profile

Using Next Generation Sequencing of Flow Cytometry CD Markers and Machine Learning As a Replacement to Flow Cytometry Analysis for the Diagnosis of Hematologic Neoplasms

DNA and RNA Profiles in Machine Learning Algorithm to Predict Which Patients with AML/MDS Will Respond to Venetoclax-Based Therapy

Dose-Intense Frontline Chemotherapy Changes Molecular Classifier Prognostication in Diffuse Large B-Cell Lymphoma(DLBCL)

Liquid Immunophenotyping and the Diagnosis of Lymphoid Neoplasms Using Cell-Free RNA

Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium

Real-World Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Standard of Care: A Cota Database Analysis

Using Targeted Transcriptome and Machine Learning of Pre- and Post-Transplant Bone Marrow Samples to Predict Acute Gvhd (aGVHD) and Overall Survival after Allogeneic HSC Transplantation

Reliability of Cell-Free DNA (cfDNA) Next Generation Sequencing in Predicting Chromosomal Structural Abnormalities and Cytogenetic-Risk Stratification of Patients with Myeloid Neoplasms

A Multi-Center Retrospective Study of Polatuzumab for Patients with Large B-Cell Lymphoma Relapsed after Standard of Care CAR T-Cell Therapy

Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only